Fukunaga Y, Itoh H, Doi K, Tanaka T, Yamashita J, Chun T H, Inoue M, Masatsugu K, Sawada N, Saito T, Hosoda K, Kook H, Ueda M, Nakao K
Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8397, Japan.
Atherosclerosis. 2001 Sep;158(1):113-9. doi: 10.1016/s0021-9150(01)00430-0.
Insulin resistance has been highlighted as a common causal factor for glucose intolerance, hypertension and dyslipidemia, all of which are cardiovascular risk factors. A new class of antidiabetic agents, thiazolidinediones (TZDs), has been developed and demonstrated to improve insulin sensitivity. TZDs are high affinity ligands for peroxisome proliferator-activated receptor gamma (PPARgamma), the crucial transcription factor for adipocytes. Recent studies showed that PPARgamma is also expressed in monocytes/macrophages and is suggested to be involved in atherosclerosis. We could detect PPARgamma gene transcript in several cultured endothelial cells (human aortic endothelial cells (HAoECs), human coronary artery endothelial cells (HCAECs), human umbilical vein endothelial cells (HUVECs) and bovine carotid artery endothelial cells (BAECs)) as well as human coronary arteries we examined. Since endothelial dysfunction is critical for atherosclerosis, we investigated the effects of TZDs, troglitazone (TRO) and pioglitazone (PIO), on endothelial cell growth and secretion of C-type natriuretic peptide (CNP), which we demonstrated as a novel endothelium-derived relaxing peptide, and endothelin (ET), a potent vasoconstrictor, using HAoECs, HCAECs, HUVECs and BAECs. When all these cultured endothelial cells were daily treated with TRO and PIO for 5 days, both TRO and PIO (10(-8)M) significantly stimulated (3)H-thymidine incorporation of all these endothelial cells. In contrast, higher dose of TRO and PIO (10(-5)M) significantly suppressed DNA synthesis. TRO and PIO also exerted the compatible effect on the increase of cell numbers. TRO and PIO significantly enhanced CNP secretion from BAECs. In contrast, ET secretion from BAECs was suppressed by both TRO and PIO in a dose-dependent manner. The results of the present study suggest that TZDs modulate endothelial functions, including regulation of endothelial cell growth and secretion of endothelium-derived vasoactive substances, which affect vascular tone and remodeling in the process of atherosclerosis.
胰岛素抵抗已被视为导致葡萄糖耐受不良、高血压和血脂异常的常见病因,而这些均为心血管危险因素。一类新型抗糖尿病药物——噻唑烷二酮类(TZDs)已被研发出来,并证实可改善胰岛素敏感性。TZDs是过氧化物酶体增殖物激活受体γ(PPARγ)的高亲和力配体,PPARγ是脂肪细胞的关键转录因子。最近的研究表明,PPARγ也在单核细胞/巨噬细胞中表达,并被认为与动脉粥样硬化有关。我们能够在几种培养的内皮细胞(人主动脉内皮细胞(HAoECs)、人冠状动脉内皮细胞(HCAECs)、人脐静脉内皮细胞(HUVECs)和牛颈动脉内皮细胞(BAECs))以及我们所检测的人冠状动脉中检测到PPARγ基因转录本。由于内皮功能障碍对动脉粥样硬化至关重要,我们使用HAoECs、HCAECs、HUVECs和BAECs研究了TZDs、曲格列酮(TRO)和吡格列酮(PIO)对内皮细胞生长以及C型利钠肽(CNP,我们已证实其为一种新型内皮源性舒张肽)和内皮素(ET,一种强效血管收缩剂)分泌的影响。当所有这些培养的内皮细胞每天用TRO和PIO处理5天时,TRO和PIO(10⁻⁸M)均显著刺激了所有这些内皮细胞的³H-胸腺嘧啶核苷掺入。相比之下,更高剂量的TRO和PIO(10⁻⁵M)则显著抑制了DNA合成。TRO和PIO对细胞数量的增加也有类似作用。TRO和PIO显著增强了BAECs中CNP的分泌。相比之下,TRO和PIO均以剂量依赖的方式抑制了BAECs中ET的分泌。本研究结果表明,TZDs可调节内皮功能,包括调节内皮细胞生长以及内皮源性血管活性物质的分泌,这些在内动脉粥样硬化过程中会影响血管张力和重塑。